Artivila Lands ￥150 Million Series Pre-A Funding

(VCBeat) Mar. 31, 2021 -- Artivila Therapeutics Co., Ltd. ("Artivila") announced the close of a ￥150 million Series Pre-A investment round, led by Highlight Capital, with participation from Med-Fine Capital and Yijing Investment.

The funds are earmarked for the development and expansion of Artivila's pipeline, optimization of the computing and AI-based R&D platform, construction of new R&D laboratories and purchasing of equipment.

Cofounded by senior drug design experts and R&D managers in the biomedical industry, Artivila's founding team has many years of experience in computational chemistry and medicinal chemistry with branches in Shenzhen, Beijing, and Boston. Artivila focuses on the design of new drugs driven by computational chemistry, and is committed to becoming an intelligent R&D company of innovative drugs.

Dr. Zhendong Zhu, Chairman of  Artivila, said, "We are pleased to receive strong support from the investors led by Highlight Capital in this round of financing. Adhered to the philosophy of 'AI + HI (Human Intelligence)', we apply new drug design technologies to target selection and compound design to improve the speed and efficiency of new drug development. Artivila has built a rich product line in a relatively short period of time, mainly thanks to the application of AI and HI."

HLC is a health industry-focused fund. It is dedicated to investing in leading life science enterprises that provide innovative products and services to advance diagnosis and treatment of diseases and to promote healthy living. With extensive experience, the company has established a strong presence across sub-sectors such as biotechnology (innovative therapeutics, CRO/CMO, etc.), medical technology (medical devices, IVD, etc.), and consumer health (hospital chains, personal care, etc.).

Founded in 2014 at China's financial hub-Shanghai, Med-Fine Capital is an investment fund. Currently, it manages11 investment funds, of which the amount value has reached nearly 800 million yuan.

Med-Fine Capital mainly invests in the healthcare and bioscience industry. The financial services include equity investments (VC/PE), PIPE, FOF (Fund of Funds), securities investing, M&A and etc.